

Exhibit 6



US006630507B1

(12) **United States Patent**
Hampson et al.

(10) **Patent No.:** US 6,630,507 B1
 (45) **Date of Patent:** Oct. 7, 2003

(54) **CANNABINOID AS ANTIOXIDANTS AND NEUROPROTECTANTS**

(75) Inventors: **Aidan J. Hampson**, Irvine, CA (US);
Julius Axelrod, Rockville, MD (US);
Maurizio Grimaldi, Bethesda, MD (US)

(73) Assignee: **The United States of America as represented by the Department of Health and Human Services**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/674,028**

(22) PCT Filed: **Apr. 21, 1999**

(86) PCT No.: **PCT/US99/08769**

§ 371 (c)(1),
 (2), (4) Date: **Feb. 2, 2001**

(87) PCT Pub. No.: **WO99/53917**

PCT Pub. Date: **Oct. 28, 1999**

Related U.S. Application Data

(60) Provisional application No. 60/082,589, filed on Apr. 21, 1998, and provisional application No. 60/095,993, filed on Aug. 10, 1998.

(51) **Int. Cl.⁷** **A61K 31/35**

(52) **U.S. Cl.** **514/454**

(58) **Field of Search** **514/454**

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,304,669 A	12/1942	Adams	568/743
4,876,276 A	10/1989	Mechoulam et al.	514/454
5,227,537 A	7/1993	Stoss et al.	568/811
5,284,867 A	2/1994	Kloog et al.	514/454
5,434,295 A	7/1995	Mechoulam et al.	560/141
5,462,946 A	10/1995	Mitchell et al.	514/315
5,512,270 A	4/1996	Ghio et al.	424/45
5,521,215 A	5/1996	Mechoulam et al.	514/454
5,538,993 A	7/1996	Mechoulam et al.	514/454
5,635,530 A	6/1997	Mechoulam et al.	514/454
5,696,109 A	12/1997	Malfroy-Camine et al.	514/185
6,410,588 B1	6/2002	Feldmann et al.	514/454

FOREIGN PATENT DOCUMENTS

EP	427518 A1	5/1991
EP	576357 A1	12/1993
EP	656354 A1	6/1995
EP	658546 A1	6/1995
WO	WO9305031 A1	3/1993
WO	WO9412667 A1	6/1994
WO	WO9612485 A1	5/1996
WO	WO9618600 A1	6/1996
WO	WO9719063 A1	5/1997
WO	99/53917	* 10/1999

OTHER PUBLICATIONS


Windholz et al., *The Merck Index*, Tenth Edition (1983) p. 241, abstract No. 1723.*
 Mechoulam et al., "A Total Synthesis of d1-Δ¹-Tetrahydrocannabinol, the Active Constituent of Hashish¹," *Journal of the American Chemical Society*, 87:14:3273-3275 (1965).
 Mechoulam et al., "Chemical Basis of Hashish Activity," *Science*, 18:611-612 (1970).
 Ottersen et al., "The Crystal and Molecular Structure of Cannabidiol," *Acta Chem. Scand. B 31*, 9:807-812 (1977).
 Cunha et al., "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients¹," *Pharmacology*, 21:175-185 (1980).
 Consroe et al., "Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats," *Experimental Neurology*, Academic Press Inc., 70:626-637 (1980).
 Turkkanis et al., "Electrophysiologic Properties of the Cannabinoids," *J. Clin. Pharmacol.*, 21:449S-463S (1981).
 Carlini et al., "Hypnotic and Antiepileptic Effects of Cannabidiol," *J. Clin. Pharmacol.*, 21:417S-427S (1981).
 Karler et al., "The Cannabinoids as Potential Antiepileptics," *J. Clin. Pharmacol.*, 21:437S-448S (1981).
 Consroe et al., "Antiepileptic Potential of Cannabidiol Analogs," *J. Clin. Pharmacol.*, 21:428S-436S (1981).

(List continued on next page.)

Primary Examiner—Kevin E. Weddington
 (74) *Attorney, Agent, or Firm*—Klarquist Sparkman, LLP
 (57) **ABSTRACT**

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH₃, and COCH₃.

(I)



26 Claims, 7 Drawing Sheets

US 6,630,507 B1

Page 2

OTHER PUBLICATIONS

- Colasanti et al., "Ocular Hypotension, Ocular Toxicity, and Neurotoxicity in Response to Marijuana Extract and Cannabidiol," *Gen Pharm.*, Pergamon Press Ltd., 15(6):479-484 (1984).
- Colasanti et al., "Intraocular Pressure, Ocular Toxicity and Neurotoxicity after Administration of Cannabinol or Cannabigerol," *Exp. Eye Res.*, Academic Press Inc., 39:251-259 (1984).
- Volfe et al., "Cannabinoids Block Release of Serotonin from Platelets Induced by Plasma from Migraine Patients," *Int. J. Clin. Pharm. Res.*, Bioscience Ediprint Inc., 4:243-246 (1985).
- Agurell et al., "Pharmacokinetics and Metabolism of Δ^1 -Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*," *Pharmacological Reviews*, 38(1):21-43 (1986).
- Karler et al., "Different Cannabinoids Exhibit Different Pharmacological and Toxicological Properties," *NIDA Res. Monogr.*, 79:96-107 (1987).
- Samara et al., "Pharmacokinetics of Cannabidiol in Dogs," *Drug Metabolism and Disposition*, 16(3):469-472 (1988).
- Choi, "Glutamate Neurotoxicity and Diseases of the Nervous System," *Neuron*, Cell Press, 1:623-634 (1988).
- Eshhar et al., "Neuroprotective and Antioxidant Activities of HU-211, A Novel NMDA Receptor Antagonist," *European Journal of Pharmacology*, 283:19-29 (1995).
- Skaper et al., "The ALLAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Granule Neurons," *Neurobiology*, Proc. Natl. Acad. Sci. USA, 93:3984-3989 (1996).
- Alonso et al., "Simple Synthesis of 5-Substituted Resorcinols: A Revisited Family of Interesting Bioactive Molecules," *J. Org. Chem.*, American Chemical Society, 62(2):417-421 (1997).
- Combes et al., "A Simple Synthesis of the Natural 2,5-Dialkylresorcinol Free Radical Scavenger Antioxidant: Resorstatin," *Synthetic Communications*, Marcel Dekker, Inc., 27(21):3769-3778 (1997).
- Shohami et al., "Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome," *Journal of Cerebral Blood Flow and Metabolism*, Lippincott-Raven Publishers, 17(10):1007-1019 (1997).
- Zurier et al., "Dimethylheptyl-THC-11 OIC Acid," *Arthritis & Rheumatism*, 41(1):163-170 (1998).
- Hampson et al., "Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission," *Journal of Neurochemistry*, Lippincott-Raven Publishers, 70(2):671-676 (1998).
- Hampson et al., "Cannabidiol and (-) Δ^9 -tetrahydrocannabinol are Neuroprotective Antioxidants," *Medical Sciences*, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998).

* cited by examiner

FIG. 1




FIG. 2




FIG. 4




FIG. 3




FIG. 5




FIG. 6




FIG. 7




FIG. 8

